Improving beta‐cell secretory function and glycaemia in young‐onset type 2 diabetes: A pilot, 12‐month, randomized trial of a novel, continuous glucose monitor‐guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a small (n=20) open-label pilot RCT in Australian adults with EOT2D demonstrated that rapid titration of medication (metformin [1 g/day–2 g/day]±empagliflozin [10 mg/day–25 mg/day]±liraglutide [1.2 mg/day–1.8 mg/day]), guided by the use of continuous glucose monitoring (CGM), improved β-cell function (measured using the insulin secretion-sensitivity index-2) at 6 and 12 months, when compared with”
From Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions (2025) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y., Zhou, Z., Yan, X., Tian, H., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60762-x · Cited by 780
Long-term complications in youth-onset type 2 diabetes
TODAY Study Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100165 · Cited by 546
Relationship between glycated haemoglobin levels and mean glucose levels over time
Nathan, D. M., Turgeon, H., & Regan, S. (2007) · Diabetologia · doi:10.1007/s00125-007-0803-0 · Cited by 517 · cited 1×
“5%.(13) If CGM data revealed a mean blood glucose level (BGL) ≥7.”
BackgroundThe RISE Consortium, Nadeau, K. J., Hannon, T. S., Edelstein, S. L., Arslanian, S. A., Caprio, S., Leschek, E. W., Zeitler, P. S., Buchanan, T. A., Ehrmann, D. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0787 · Cited by 176 · cited 5×
“Although early improvement of glucotoxicity has long been postulated to have beneficial effects on the β-cell,5 the promise of first-line insulin treatment has not been shown to be of benefit in YT2D.4 Interestingly, there is an increasing body of evidence suggesting that glucagon-like peptide-1 receptor agonist and s…”
BackgroundInfluentialThe RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0556 · Cited by 73 · cited 1×
“treatment in youth followed by metformin nor early use of liraglutide and metformin alone in adults attenuated progressive functional β-cell decline.(4,16) Clearly, greater durability of glycaemic benefit and persistence of functional β-cell improvement needs to be definitively proven before any new treatment paradigm…”
Background
Research works printed but not linked: 10
- 10.2337/dc15-0991 · DOI · Paper page
- 10.1111/dme.14238 · DOI · Paper page
- 10.2337/diabetes.48.12.2270 · DOI · Paper page
- 10.1152/ajpendo.00030.2002 · DOI · Paper page
- 10.1111/1753-0407.12494 · DOI
- 10.1111/dom.14205 · DOI
- 10.1111/dom.14192 · DOI · Paper page
- 10.4236/jbise.2011.411090 · DOI · Paper page
- 10.1038/oby.2008.307 · DOI · Paper page
- 10.1111/j.1464-5491.2009.02841.x · DOI · Paper page
Cited by
Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions
Savage, M. J., Goldney, J., Slater, T., Sarkar, P., Sargeant, J. A., Wilmot, E. G., & Davies, M. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0561 · Cited by 11
Metadata
- Authors
- Middleton, T. L., Constantino, M. I., McGill, M., D’Souza, M., Yue, D. K., Twigg, S. M., Wu, T., & Wong, J.
- Affiliations
- Diabetes Centre Royal Prince Alfred Hospital Camperdown New South Wales Australia
- Sydney Local Health District Clinical Research Centre Camperdown New South Wales Australia
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2021-12-28
- Volume
- 24
- Issue
- 4
- Pages
- 747-751
- ISSN
- 1462-8902
- 1463-1326
- Cited by
- 2
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.